All News

Findings underscore a need for public health initiatives to educate vulnerable populations on cardiometabolic risks, researchers report.

Your daily dose of the clinical news you may have missed.

A concise update on legal status, FDA approvals, patient safety, and public perception.

Your daily dose of the clinical news you may have missed.

The 3% decline in 2023 compared with 2022 is "heartening news," CDC's Houry says, but the mission is far from accomplished.

DDW 2024. An investigational blood-based screening test demonstrated nearly a 80% sensitivity for detecting CRC, according to a large prospective study.

Adults with undiagnosed asthma or COPD who were randomly detected and assigned to specialist or usual care all had improved outcomes at 1 year, Canadian authors reported.

Which state has the lowest percentage of teen drug users? Or the highest percentage of adults with unmet drug-treatment needs? Answers from a new report, here.

Women with class 3 obesity before becoming pregnant have up to a 4.5-fold greater risk of composite maternal morbidity that includes preeclampsia, preterm delivery, DM.

Your daily dose of the clinical news you may have missed.

Data presented at ACOG 2024 suggest SARS-CoV-2 infection early in pregnancy can lead to a higher likelihood of preeclampsia, as well as more severe disease.

Dupilumab reduced COPD exacerbations by 34% in adults with uncontrolled symptoms and evidence of T2 inflammation, and significantly improved lung function.

DDW 24. New research shows patients with MASLD and T2D who used GLP-1 agonists had a reduced risk of progression to cirrhosis and HCC vs non-users.

Your daily dose of the clinical news you may have missed.

Dave Singh, MD, lead investigator for the phase 2a COURSE trial of tezepelumab in moderate to very severe COPD, highlights the drug's promise in vulnerable groups.

ATS: The biologic shows promise in a range of people with COPD, particularly those with BEC levels of 150 cells/μL and greater, according to findings released at the 2024 ATS meeting.

The triple therapy cut risk of a first cardiopulmonary event by 20% vs dual therapy in addition to significantly reducing COPD exacerbations, PI Singh told Patient Care.

Men with diabetes had a greater risk of CVD, lower limb and kidney complications, and diabetic retinopathy compared to women with diabetes.